Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Profit After Tax: 2015-2025

Historic Profit After Tax for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$25.1 million.

  • Editas Medicine's Profit After Tax rose 59.58% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.8 million, marking a year-over-year increase of 5.10%. This contributed to the annual value of -$237.1 million for FY2024, which is 54.74% down from last year.
  • Per Editas Medicine's latest filing, its Profit After Tax stood at -$25.1 million for Q3 2025, which was up 52.82% from -$53.2 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Profit After Tax ranged from a high of -$18.9 million in Q4 2023 and a low of -$76.1 million during Q1 2025.
  • For the 3-year period, Editas Medicine's Profit After Tax averaged around -$49.5 million, with its median value being -$49.0 million (2023).
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 599.83% in 2021, then spiked by 68.93% in 2023.
  • Quarterly analysis of 5 years shows Editas Medicine's Profit After Tax stood at -$41.4 million in 2021, then crashed by 46.58% to -$60.7 million in 2022, then surged by 68.93% to -$18.9 million in 2023, then slumped by 140.52% to -$45.4 million in 2024, then soared by 59.58% to -$25.1 million in 2025.
  • Its Profit After Tax was -$25.1 million in Q3 2025, compared to -$53.2 million in Q2 2025 and -$76.1 million in Q1 2025.